One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Table of Contents
doi : 10.1016/S0923-7534(21)04502-6
Volume 32, Issue 11, November 2021, Pages i-ii
Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets?
I.Melero123N.Normanno4
Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective
R.Salgado12V.Peg345J.Rüschoff6A.Vincent-Salomon7I.Castellano8S.Perner910K.Van de Vijver11C.M.Quinn12Z.Varga13
Brain metastases in solid tumours: new guidelines for a new era
S.Popat123L.Welsh34
Precision guidelines for soft tissue and visceral sarcomas: the evidence, expert experience and ensuring optimal care for rare cancers, a 2021 update from ESMO–EURACAN–GENTURIS
R.A.Gladdy
Fifty years of clinical and research studies for childhood renal tumors within the International Society of Pediatric Oncology (SIOP)
N.Graf1C.Bergeron2J.Brok3B.de Camargo4T.Chowdhury5R.Furtwängler1M.Gessler6J.Godzinski78K.Pritchard-Jones9G.L.Ramirez-Villar10C.Rübe11B.Sandstedt12J.-P.Schenk13F.Spreafico14H.Sudour-Bonnange15H.van Tinteren16A.Verschuur17G.Vujanic18M.M.van den Heuvel-Eibrink16
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
E.Le Rhun12M.Guckenberger3M.Smits4R.Dummer5T.Bachelot6F.Sahm7N.Galldiks8910E.de Azambuja11A.S.Berghoff12P.Metellus1314S.Peters15Y.-K.Hong16F.Winkler17D.Schadendorf1819M.van den Bent20J.Seoane2122R.Stahel23G.Minniti2425…M.Preusser12
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
A.Gronchi1A.B.Miah2A.P.Dei Tos3N.Abecassis4J.Bajpai5S.Bauer6R.Biagini7S.Bielack8J.Y.Blay9S.Bolle10S.Bonvalot11I.Boukovinas12J.V.M.G.Bovee13K.Boye14B.Brennan15T.Brodowicz16A.Buonadonna17E.De �lava1819…S.Stacchiotti26
Early-phenotype CAR-T cells for the treatment of pediatric cancers
D.Meyran123†R.L.Terry45†J.J.Zhu13M.Haber45D.S.Ziegler456P.G.Ekert1457J.A.Trapani13‡P.K.Darcy13‡P.J.Neeson13‡
Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance
Y.Loriot1†A.Marabelle2†J.P.Guégan3F.X.Danlos2B.Besse14N.Chaput567C.Massard2D.Planchard1C.Robert1C.Even1M.Khettab1L.Tselikas8L.Friboulet9F.André14I.Nafia3F.Le Loarer1011J.C.Soria1A.Bessede3‡A.Italiano21112‡
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy
A.Cortellini12B.Ricciuti3F.Facchinetti4J.V.M.Alessi3D.Venkatraman3F.G.Dall'Olio5P.Cravero3V.R.Vaz3D.Ottaviani6M.Majem7A.Piedra7I.Sullivan7K.A.Lee89G.Lamberti10N.Hussain2J.Clark2A.Bolina2A.Barba7…D.J.Pinato215
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status
G.A.Croci123†R.K.H.Au-Yeung14†S.Reinke1A.M.Staiger56K.Koch1I.Oschlies1J.Richter1V.Poeschel7G.Held8M.Loeffler9L.Trümper10A.Rosenwald11G.Ott56R.Spang12B.Altmann8M.Ziepert9†W.Klapper1â€
Outcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohort
S.Schrodi1M.Braun2A.Andrulat2N.Harbeck3S.Mahner3M.Kiechle4E.Klein4A.Schnelzer5C.Schindlbeck36I.Bauerfeind7G.Schubert-Fritschle1V.Nekljudova8D.Mayr9W.Weichert10C.Denkert11S.Loibl812J.Engel1
A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility
I.M.Modlin1M.Kidd2M.Falconi3P.L.Filosso4A.Frilling5A.Malczewska6C.Toumpanakis7G.Valk8K.Pacak9L.Bodei10K.E.Öberg11
Large-scale prospective genome-wide association study of oxaliplatin in stage II/III colon cancer and neuropathy
M.Kanai1T.Kawaguchi2M.Kotaka3D.Manaka4J.Hasegawa5A.Takagane6Y.Munemoto7T.Kato8T.Eto9T.Touyama10T.Matsui11K.Shinozaki12S.Matsumoto13T.Mizushima14M.Mori15J.Sakamoto1617A.Ohtsu18T.Yoshino18…F.Matsuda2
Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL
M.van Gelder1O.Tournilhac2D.te Raa3H.P.J.Visser4
Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients
P.Heudel1B.Favier2S.Assaad1P.Zrounba3J.-Y.Blay145
Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies
F.Pommeret1J.Colomba1C.Bigenwald2A.Laparra3S.Bockel4A.Bayle3J.-M.Michot3T.Hueso2L.Albiges1P.Tiberghien56S.Marot7A.Jary7K.Lacombe8F.Barlesi19F.Griscelli10E.Colomba1
Significant response of medullary thyroid cancer choroidal metastases to highly selective RET inhibitor selpercatinib: a case report
A.Matrone1A.Prete1M.S.Sartini2R.Elisei1
Progressive melanoma versus tumor melanosis: is imaging enough?
T.M.Davidson1S.N.Markovic2M.S.Block2R.Guo3
Inflammation reduces the effect of nutritional therapy on clinical outcomes in cancer patients
L.Bargetzi1M.Bargetzi12A.Laviano3Z.Stanga4P.Schuetz12
Corrigendum to “Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up�: [Annals of Oncology 32 (2021) 439–451]
E.Baudin1M.Caplin2R.Garcia-Carbonero3N.Fazio4P.Ferolla5P.L.Filosso6A.Frilling7W.W.de Herder8D.Hörsch9U.Knigge10C.M.Korse11E.Lim12C.Lombard-Bohas13M.Pavel14J.Y.Scoazec15A.Sundin16A.Berruti17ESMO Guidelines Committee
